Tumor antigen-specific T cells for immune monitoring of dendritic cell-treated glioblastoma patients.

[1]  T. Blankenstein,et al.  Targeting human melanoma neoantigens by T cell receptor gene therapy. , 2016, The Journal of clinical investigation.

[2]  Yusuke Nakamura,et al.  Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation , 2015, Clinical Cancer Research.

[3]  S. Gool.  Brain Tumor Immunotherapy: What have We Learned so Far? , 2015, Front. Oncol..

[4]  James M. Olson,et al.  A technology platform to assess multiple cancer agents simultaneously within a patient’s tumor , 2015, Science Translational Medicine.

[5]  Robert Langer,et al.  An implantable microdevice to perform high-throughput in vivo drug sensitivity testing in tumors , 2015, Science Translational Medicine.

[6]  H. Eichler,et al.  Static Image Analysis as New Approach for the Characterization of Tumor Cell Lysate Used in Dendritic Cell Vaccine Preparation , 2015, Transfusion Medicine and Hemotherapy.

[7]  Y. Mao,et al.  Glioma-Associated Antigen HEATR1 Induces Functional Cytotoxic T Lymphocytes in Patients with Glioma , 2014, Journal of immunology research.

[8]  K. Black,et al.  Intrinsically de-sialylated CD103+ CD8 T cells mediate beneficial anti-glioma immune responses , 2014, Cancer Immunology, Immunotherapy.

[9]  R. Zheng,et al.  The Role of the γ δ T Cell in Allergic Diseases , 2014, Journal of immunology research.

[10]  F. Zufall,et al.  A simple, economic, time‐resolved killing assay , 2014, European journal of immunology.

[11]  S. Nair,et al.  Recognition and Killing of Autologous, Primary Glioblastoma Tumor Cells by Human Cytomegalovirus pp65-Specific Cytotoxic T Cells , 2014, Clinical Cancer Research.

[12]  C. Pinilla,et al.  Identification of Novel Human Leukocyte Antigen‐A*0201‐Restricted, Cytotoxic T Lymphocyte Epitopes on CD133 for Cancer Stem Cell Immunotherapy , 2014, Stem cells translational medicine.

[13]  J. Kirkwood,et al.  Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab , 2014, PloS one.

[14]  Deepali Kumar,et al.  Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation , 2014, Clinical & translational immunology.

[15]  Johannes Hain,et al.  Development and validation of a fully GMP-compliant production process of autologous, tumor-lysate-pulsed dendritic cells. , 2013, Cytotherapy.

[16]  I. Hermans,et al.  Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme , 2014, Journal of Neuro-Oncology.

[17]  W. Henn,et al.  Establishment of a molecular cytogenetic analysis for native tumor tissue of meningiomas-suitable for clinical application , 2014, Molecular Cytogenetics.

[18]  E. Proietti,et al.  Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays , 2013, BioMed research international.

[19]  L. Ellerbroek,et al.  Serotype Distribution of Salmonella Isolates from Turkey Ground Meat and Meat Parts , 2013, BioMed research international.

[20]  T. Ashizawa,et al.  α-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial , 2012, BMC Cancer.

[21]  Hiroaki Tanaka,et al.  Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival , 2012, Nature Medicine.

[22]  S. Phuphanich,et al.  Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma , 2012, Cancer Immunology, Immunotherapy.

[23]  Wen-Yuan Lee,et al.  Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. , 2012, World neurosurgery.

[24]  Hans-Georg Rammensee,et al.  Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. , 2012, Brain : a journal of neurology.

[25]  Y. Yamashita,et al.  Ex Vivo Expansion of Human CD8+ T Cells Using Autologous CD4+ T Cell Help , 2012, PloS one.

[26]  T. Kubota,et al.  A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma , 2011, Journal of Clinical Neuroscience.

[27]  H. Wishart,et al.  Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy , 2011, Journal of immunotherapy.

[28]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[29]  J. Engh,et al.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Clinical Application of a Dendritic Cell Vaccine Raised Against Heat-Shocked Glioblastoma , 2011, Cell Biochemistry and Biophysics.

[31]  P. Greenberg,et al.  Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy , 2011, Cancer Immunology, Immunotherapy.

[32]  S. Nelson,et al.  Gene Expression Profile Correlates with T-Cell Infiltration and Relative Survival in Glioblastoma Patients Vaccinated with Dendritic Cell Immunotherapy , 2010, Clinical Cancer Research.

[33]  C. Rooney,et al.  Enhancement of dendritic cells as vaccines for cancer. , 2010, Immunotherapy.

[34]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  S. Rosenberg,et al.  Successful Treatment of Melanoma Brain Metastases with Adoptive Cell Therapy , 2010, Clinical Cancer Research.

[36]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[37]  C. Kramm,et al.  Adjuvant dendritic cell‐based tumour vaccination for children with malignant brain tumours , 2010, Pediatric blood & cancer.

[38]  Jan Goffin,et al.  Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study , 2010, Journal of Neuro-Oncology.

[39]  Sylvia Janetzki,et al.  "MIATA"-minimal information about T cell assays. , 2009, Immunity.

[40]  R. McLendon,et al.  EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma , 2009, Brain pathology.

[41]  S. Rosenberg,et al.  Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. , 2009, Blood.

[42]  I. Pastan,et al.  Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains , 2009, Proceedings of the National Academy of Sciences.

[43]  H. Ikeda,et al.  Tumor progression inhibits the induction of multifunctionality in adoptively transferred tumor‐specific CD8+ T cells , 2009, European journal of immunology.

[44]  Bastian R. Angermann,et al.  Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses , 2008, The Journal of experimental medicine.

[45]  J. Villeneuve,et al.  Early Interferon Therapy for Hepatitis C Virus Infection Rescues Polyfunctional, Long-Lived CD8+ Memory T Cells , 2008, Journal of Virology.

[46]  K. Black,et al.  Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. , 2008, Cancer research.

[47]  R. Sciot,et al.  Postoperative Adjuvant Dendritic Cell–Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme , 2008, Clinical Cancer Research.

[48]  M. Roederer,et al.  T-cell quality in memory and protection: implications for vaccine design , 2008, Nature Reviews Immunology.

[49]  F. Tomlinson,et al.  Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy , 2008, Journal of Clinical Neuroscience.

[50]  D. Kondziolka,et al.  Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas , 2007, Journal of Translational Medicine.

[51]  A. Anichini,et al.  Unique Tumor Antigens: Evidence for Immune Control of Genome Integrity and Immunogenic Targets for T Cell–Mediated Patient-Specific Immunotherapy , 2006, Clinical Cancer Research.

[52]  A. Friedman,et al.  Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. , 2006, Cancer research.

[53]  Timothy F. Cloughesy,et al.  Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor Microenvironment , 2005, Clinical Cancer Research.

[54]  Naoto Tsuchiya,et al.  Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[55]  T. Blankenstein.  The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.

[56]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[57]  S. Mocellin,et al.  Part II: Vaccines for haematological malignant disorders. , 2004, The Lancet. Oncology.

[58]  Simone Mocellin,et al.  Part I: Vaccines for solid tumours. , 2004, The Lancet. Oncology.

[59]  D. Kufe,et al.  Vaccination of Glioma Patients with Fusions of Dendritic and Glioma Cells and Recombinant Human Interleukin 12 , 2004, Journal of immunotherapy.

[60]  P. Flamen,et al.  Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study , 2004, British Journal of Cancer.

[61]  Keith L Black,et al.  Clinical Responsiveness of Glioblastoma Multiforme to Chemotherapy after Vaccination , 2004, Clinical Cancer Research.

[62]  Keith L. Black,et al.  Vaccination with Tumor Lysate-Pulsed Dendritic Cells Elicits Antigen-Specific, Cytotoxic T-Cells in Patients with Malignant Glioma , 2004, Cancer Research.

[63]  K. Black,et al.  HER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells , 2004, Cancer Research.

[64]  R. Sciot,et al.  Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. , 2004, Journal of neurosurgery.

[65]  K. Black,et al.  Thymic CD8+ T Cell Production Strongly Influences Tumor Antigen Recognition and Age-Dependent Glioma Mortality 1 , 2003, The Journal of Immunology.

[66]  R. Tanaka,et al.  Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial , 2003, British Journal of Cancer.

[67]  Donna Niedzwiecki,et al.  Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. , 2003, Cancer research.

[68]  M. Smyth,et al.  Interferon-gamma-dependent phagocytic cells are a critical component of innate immunity against metastatic mammary carcinoma. , 2002, Cancer research.

[69]  T. Ohno,et al.  Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells , 2001, Cancer Immunology, Immunotherapy.

[70]  H. Lyerly,et al.  Assays for monitoring cellular immune responses to active immunotherapy of cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[71]  K. Black,et al.  Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. , 2001, Cancer research.

[72]  A. Belldegrun,et al.  Treatment of a glioblastoma patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides , 2000 .

[73]  B. Boehm,et al.  Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. , 2000, Journal of immunological methods.

[74]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.